|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PSMG2 |
Gene summary for PSMG2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PSMG2 | Gene ID | 56984 |
| Gene name | proteasome assembly chaperone 2 | |
| Gene Alias | CLAST3 | |
| Cytomap | 18p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q969U7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56984 | PSMG2 | LZE4T | Human | Esophagus | ESCC | 2.49e-13 | 5.65e-01 | 0.0811 |
| 56984 | PSMG2 | LZE5T | Human | Esophagus | ESCC | 8.77e-04 | 4.90e-01 | 0.0514 |
| 56984 | PSMG2 | LZE7T | Human | Esophagus | ESCC | 1.59e-07 | 8.25e-01 | 0.0667 |
| 56984 | PSMG2 | LZE8T | Human | Esophagus | ESCC | 1.33e-10 | 5.85e-01 | 0.067 |
| 56984 | PSMG2 | LZE20T | Human | Esophagus | ESCC | 1.66e-09 | 2.91e-01 | 0.0662 |
| 56984 | PSMG2 | LZE24T | Human | Esophagus | ESCC | 1.48e-20 | 9.05e-01 | 0.0596 |
| 56984 | PSMG2 | LZE21T | Human | Esophagus | ESCC | 2.57e-04 | 5.49e-01 | 0.0655 |
| 56984 | PSMG2 | P1T-E | Human | Esophagus | ESCC | 6.12e-05 | 6.60e-01 | 0.0875 |
| 56984 | PSMG2 | P2T-E | Human | Esophagus | ESCC | 1.09e-39 | 9.53e-01 | 0.1177 |
| 56984 | PSMG2 | P4T-E | Human | Esophagus | ESCC | 5.65e-48 | 1.38e+00 | 0.1323 |
| 56984 | PSMG2 | P5T-E | Human | Esophagus | ESCC | 1.46e-61 | 1.44e+00 | 0.1327 |
| 56984 | PSMG2 | P8T-E | Human | Esophagus | ESCC | 5.32e-45 | 9.27e-01 | 0.0889 |
| 56984 | PSMG2 | P9T-E | Human | Esophagus | ESCC | 9.21e-31 | 1.07e+00 | 0.1131 |
| 56984 | PSMG2 | P10T-E | Human | Esophagus | ESCC | 7.82e-35 | 6.82e-01 | 0.116 |
| 56984 | PSMG2 | P11T-E | Human | Esophagus | ESCC | 1.02e-22 | 9.89e-01 | 0.1426 |
| 56984 | PSMG2 | P12T-E | Human | Esophagus | ESCC | 2.96e-57 | 1.06e+00 | 0.1122 |
| 56984 | PSMG2 | P15T-E | Human | Esophagus | ESCC | 3.33e-52 | 1.27e+00 | 0.1149 |
| 56984 | PSMG2 | P16T-E | Human | Esophagus | ESCC | 3.97e-31 | 8.77e-01 | 0.1153 |
| 56984 | PSMG2 | P17T-E | Human | Esophagus | ESCC | 1.44e-09 | 8.01e-01 | 0.1278 |
| 56984 | PSMG2 | P19T-E | Human | Esophagus | ESCC | 8.92e-05 | 6.52e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005113116 | Oral cavity | OSCC | chaperone-mediated protein complex assembly | 17/7305 | 23/18723 | 7.28e-04 | 3.98e-03 | 17 |
| GO:00517842 | Oral cavity | OSCC | negative regulation of nuclear division | 34/7305 | 56/18723 | 8.17e-04 | 4.35e-03 | 34 |
| GO:00330471 | Oral cavity | OSCC | regulation of mitotic sister chromatid segregation | 29/7305 | 46/18723 | 8.26e-04 | 4.38e-03 | 29 |
| GO:00513041 | Oral cavity | OSCC | chromosome separation | 53/7305 | 96/18723 | 9.24e-04 | 4.86e-03 | 53 |
| GO:00070941 | Oral cavity | OSCC | mitotic spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
| GO:00711731 | Oral cavity | OSCC | spindle assembly checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
| GO:00711741 | Oral cavity | OSCC | mitotic spindle checkpoint | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
| GO:00458411 | Oral cavity | OSCC | negative regulation of mitotic metaphase/anaphase transition | 25/7305 | 40/18723 | 2.22e-03 | 1.00e-02 | 25 |
| GO:00330461 | Oral cavity | OSCC | negative regulation of sister chromatid segregation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
| GO:00330481 | Oral cavity | OSCC | negative regulation of mitotic sister chromatid segregation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
| GO:20008161 | Oral cavity | OSCC | negative regulation of mitotic sister chromatid separation | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
| GO:00315771 | Oral cavity | OSCC | spindle checkpoint | 24/7305 | 39/18723 | 3.64e-03 | 1.51e-02 | 24 |
| GO:19021001 | Oral cavity | OSCC | negative regulation of metaphase/anaphase transition of cell cycle | 25/7305 | 42/18723 | 5.63e-03 | 2.17e-02 | 25 |
| GO:00519851 | Oral cavity | OSCC | negative regulation of chromosome segregation | 26/7305 | 45/18723 | 8.23e-03 | 3.00e-02 | 26 |
| GO:19058191 | Oral cavity | OSCC | negative regulation of chromosome separation | 26/7305 | 45/18723 | 8.23e-03 | 3.00e-02 | 26 |
| GO:000734614 | Oral cavity | LP | regulation of mitotic cell cycle | 163/4623 | 457/18723 | 7.64e-08 | 2.56e-06 | 163 |
| GO:004477215 | Oral cavity | LP | mitotic cell cycle phase transition | 150/4623 | 424/18723 | 4.38e-07 | 1.23e-05 | 150 |
| GO:001063919 | Oral cavity | LP | negative regulation of organelle organization | 127/4623 | 348/18723 | 5.07e-07 | 1.40e-05 | 127 |
| GO:005113117 | Oral cavity | LP | chaperone-mediated protein complex assembly | 17/4623 | 23/18723 | 9.55e-07 | 2.43e-05 | 17 |
| GO:014001413 | Oral cavity | LP | mitotic nuclear division | 106/4623 | 287/18723 | 2.29e-06 | 5.10e-05 | 106 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PSMG2 | SNV | Missense_Mutation | c.492N>C | p.Glu164Asp | p.E164D | Q969U7 | protein_coding | tolerated(0.06) | probably_damaging(0.948) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PSMG2 | SNV | Missense_Mutation | novel | c.625N>A | p.Ser209Thr | p.S209T | Q969U7 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PSMG2 | insertion | In_Frame_Ins | novel | c.624_625insAAC | p.Val208_Ser209insAsn | p.V208_S209insN | Q969U7 | protein_coding | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PSMG2 | deletion | Frame_Shift_Del | c.778delN | p.Pro261LeufsTer36 | p.P261Lfs*36 | Q969U7 | protein_coding | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| PSMG2 | deletion | Frame_Shift_Del | c.26delN | p.Asp11ThrfsTer8 | p.D11Tfs*8 | Q969U7 | protein_coding | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| PSMG2 | deletion | Frame_Shift_Del | c.443delN | p.Ser150ValfsTer6 | p.S150Vfs*6 | Q969U7 | protein_coding | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| PSMG2 | SNV | Missense_Mutation | c.161N>T | p.Pro54Leu | p.P54L | Q969U7 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PSMG2 | SNV | Missense_Mutation | c.691N>A | p.Leu231Ile | p.L231I | Q969U7 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PSMG2 | SNV | Missense_Mutation | novel | c.337A>C | p.Ser113Arg | p.S113R | Q969U7 | protein_coding | tolerated(0.06) | possibly_damaging(0.872) | TCGA-AX-A2H2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PSMG2 | SNV | Missense_Mutation | novel | c.782N>T | p.Pro261Leu | p.P261L | Q969U7 | protein_coding | tolerated(0.09) | possibly_damaging(0.677) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |